Skip to content
Directory

Treatment, Medication & Supplement Directory

A comprehensive encyclopedia of medicines, chemotherapy protocols, targeted and immune therapies, supplements, Chinese herbal formulas, Traditional Chinese Veterinary Medicine (TCVM) approaches, and supportive-care options used or discussed in canine and feline tumor care. Directory entries explain what each option is, where it may fit, its evidence and safety boundaries, and what to discuss with a veterinarian; they are references, not individualized prescriptions or rankings.

Directory explains “what it is.”Guides explain how owners can discuss, use, monitor, or prepare for a treatment option with veterinary guidance.
Filter

Filter

4 directory found

Species
Product Family
See more See less
Regulatory Status
Search
4 entriesShowing 1–4
Veterinarian reviewing an immune pathway concept and an unbranded biologic treatment with a dog caregiverNamed profile Oncept Canine Melanoma Vaccine, DNA: USDA-Licensed Therapeutic BiologicRepresentative category illustration – no product packaging is shown.
Immunotherapy · Oncept · Dogs · After Targeted Therapy · Before Targeted Therapy · During Targeted Therapy · Manufacturer Information

Oncept Canine Melanoma Vaccine, DNA: USDA-Licensed Therapeutic Biologic

Oncept is a USDA-listed canine melanoma DNA biologic; license status, specialist access, intended setting, evidence limitations, and cost require current review.

Read more
Veterinary team coordinating a medication schedule for a dogNamed profile Stelfonta (Tigilanol Tiglate): Intratumoral Canine Mast Cell Tumor TherapyRepresentative category illustration – no product packaging is shown.
Prescription Drug · Targeted Therapy · Stelfonta · Dogs · After Targeted Therapy · During Targeted Therapy · Published Study

Stelfonta (Tigilanol Tiglate): Intratumoral Canine Mast Cell Tumor Therapy

Stelfonta is an FDA-approved intratumoral treatment for narrowly defined canine mast cell tumors, with important current warnings about degranulation, wounds, pain, tissue loss, amputation, and death.

Read more
Veterinarian reviewing an immune pathway concept and an unbranded biologic treatment with a dog caregiverNamed profile Gilvetmab: Canine PD-1 Immunotherapy and Conditional-Licence ProfileRepresentative category illustration – no product packaging is shown.
Immunotherapy · Prescription Drug · Gilvetmab · Dogs · During Targeted Therapy · New Diagnosis · Published Study

Gilvetmab: Canine PD-1 Immunotherapy and Conditional-Licence Profile

gilvetmab is covered as caninized anti-pd-1 monoclonal antibody immune-checkpoint inhibitor, with species, evidence, regulatory, safety, interaction and monitoring boundaries for a veterinarian-led decision.

Read more
Caregiver and veterinary professional reviewing symptom observations for a dogNamed profile H1 and H2 Blockade Around Mast-Cell Degranulation RiskRepresentative category illustration – no product packaging is shown.
Prescription Drug · Supportive-care medicine · Mast-cell mediator blockade · Dogs · During Targeted Therapy · Veterinary Clinical Use · Label-linked companion-medication context

H1 and H2 Blockade Around Mast-Cell Degranulation Risk

H1-receptor and H2-receptor blocking companion medicines is covered as protocol-linked supportive medicines; not direct antitumour treatment, with species, evidence, regulatory, safety, interaction and monitoring boundaries for a veterinarian-led…

Read more